New Scandinavian ALS drug research collaboration

Demyelination of neuron

The Division of Clinical Neuroscience at Oslo University Hospital (OUS) and the Swedish drug development company TikoMed have signed a research collaboration agreement focused on amyotrophic lateral sclerosis (ALS).

TikoMed has previously completed and reported on two successful Phase IIa clinical studies in ALS, one at the Sahlgrenska University Hospital in Sweden and one at the University of Birmingham in the UK, both with promising results.

The trial data established the safety and tolerability of ILB in people with ALS, while also indicating its future potential to be the first disease-modifying drug to treat both familial and sporadic ALS with minimal side-effects.

TikoMed’s Scientific Advisor, Professor Ann Logan, Honorary Professor of Regenerative Medicine at the University of Warwick, said: “We are very excited about the clinical potential for ILB, which may prove to be a game changing treatment for many devastating neuro-degenerative diseases.”

 The ILB treatment switches on the natural repair system of the body and is a drug addressing neuro-degenerative and neuro-inflammatory processes through endogenous activation of a repertoire of growth factors.

OUS is a highly specialised hospital in charge of extensive regional and local hospital assignments and the provision of high-quality services for the citizens of Oslo.

OUS also has nationwide responsibility for a number of national and multi-regional clinical assignments and encompasses several national centres of competence.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free